Trial Profile

A phase I study of YP 01001 in advanced solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YP 01001 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

19 Apr 2022 New trial record
24 Mar 2022 According to a YaoPharma media release, on March 17, YP01001 received approval from the National Medical Products Administration to conduct clinical trials.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com